VEGF-A

This article has been updated to clarify the enrollment challenges with the InVite Study.

Absent mature data suggesting that Genentech's biomarker strategy would likely prove Avastin's efficacy in a subpopulation, ODAC members did not want to expose patients unnecessarily to a toxic agent for many years to come.

If Genentech produces data showing substantial benefit in a subset of patients, "a new science-based indication could be approved," an FDA official said. "Until that time, it is not appropriate for the drug to continue to be approved for the treatment of breast cancer when the totality of the available data does not support such an approval."

A company spokesperson could not verify that the company will definitely discuss pharmacogenomics data on Avastin at the June 28-29 hearing.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.